- Conditions
- RSV Respiratory Syncytial Virus
- Interventions
- AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 6
- States / cities
- Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–143
of 143
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Investigational RSV vaccine MV-012-968 (Dosage 1), Investigational RSV vaccine MV-012-968 (Dosage 2), Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose), Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose), Placebo (single-dose), Placebo (two-dose)
- Biological · Other
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
- Conditions
- RSV Infection
- Interventions
- Candidate vaccine, SCB-1019T, AREXVY, placebo
- Biological · Other
- Lead sponsor
- Clover Biopharmaceuticals USA, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Not listed
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 21 Months
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Cleveland, Ohio
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine (GSK3844766A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF)
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Rockville, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection)
- Drug
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more
- Conditions
- RSV Infection
- Interventions
- Nirsevimab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 12 Months
- Enrollment
- 3,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345
- Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 36,814 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 59 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
- Interventions
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25,236 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 126 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- CodaVax-RSV, Normal Saline
- Biological
- Lead sponsor
- Codagenix, Inc
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
- Conditions
- Healthy
- Interventions
- MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 2 Months to 23 Months
- Enrollment
- 1,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
- Conditions
- Healthy
- Interventions
- RSV Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
- Conditions
- Respiratory Tract Infection
- Interventions
- RSVpreF, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years to 49 Years · Female only
- Enrollment
- 14,727 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 363
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 137 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MVA-BN-RSV, Placebo
- Biological · Other
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Redding, California • San Diego, California • The Villages, Florida + 9 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
- Interventions
- Placebo, SeVRSV Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- RSV Immunisation
- Interventions
- RSVt Vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 21 Months
- Enrollment
- 6,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV-F Particle Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas